Year: 2019
Type: review
Abstract: Cancer diagnostics and therapies have improved steadily over the last few decades, markedly increasing life expectancy for patients at all ages. However, conventional and newer anti-neoplastic therapies can cause short- and long-term cardiotoxicity. The clinical implications of this cardiotoxicity become more important with the increasing use of cardiotoxic drugs. The implications are especially serious among patients predisposed to adverse cardiac effects, such as youth, the elderly, those with cardiovascular comorbidities, and those receiving additional chemotherapies or thoracic radiation. However, the optimal strategy for preventing and managing chemotherapy-induced cardiotoxicity remains unknown. The routine use of neurohormonal antagonists for cardioprotection is not currently justified, given the marginal benefits and associated adverse events, particularly with long-term use. The only United States Food and Drug Administration and European Medicines Agency approved treatment for preventing anthracycline-related cardiomyopathy is dexrazoxane. We advocate administering dexrazoxane during cancer treatment to limit the cardiotoxic effects of anthracycline chemotherapy.
Source: Cardio-Oncology
Institutions: Montefiore Medical Center, Children's Hospital at Montefiore, University of Rochester Medicine, University of Rochester, Brigham and Women's Hospital, Lahey Hospital and Medical Center, Lahey Medical Center, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Boston Children's Hospital, Children's Hospital of Michigan, University of Zurich, Cleveland Clinic, University of Miami, Roswell Park Comprehensive Cancer Center, University at Buffalo, State University of New York
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,380
Funders: Pfizer, Children’s Hospital of Michigan Foundation, Children's Cardiomyopathy Foundation, National Institutes of Health, Roche Diagnostics, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: Pediatric Cardiomyopathy Registry, Training Program in Cardiovascular Signaling, Genetic Mechanisms of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors, Atherosclerotic Risk and Response to Exercise Intervention in HIV+ Children, Cardiovascular Status of HAART-Exposed Infants/Children, Pediatric Cardiomyopathy Specimen Repository, Pediatric HIV/AIDS Cohort Study (PHACS) Coordinating Center (CC) (U01), Therapeutic Index of Acute Lymphoblastic Leukemia, HAART Associated Cardiotoxicity in HIV-Infected Children, Primary Cardiomyopathies in Children: Research Directions & Strategies, G5560106399, Women and Infants Transmission Study IV, Baseline Predictors of Outcomes of Pediatric Dilated Cardiomyopathy, Pediatric HIV/AIDS Cohort Study (PHACS): Data and Operations Center (DOC)., FELLOWSHIP IN CLINICAL RESEARCH, G7947996496, G9000250484, Advancing Child Health Through Cellular and Molecular Biology
OpenAlex ID: W2991362566
